Polaryx Therapeutics (Direct Listing)
Note: This is NOT an IPO. This is a Direct Listing by Polaryx Therapeutics (PLYX Proposed) on the NASDAQ. Maxim Group is the financial advisor for this Direct Listing. (Incorporated in Nevada) We are a clinical-stage biotechnology company developing novel therapies for rare pediatric lysosomal storage disorders (LSDs). In the first half of 2026, we […]
February 2, 2026 Read More